The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $349,325 Project Grant under CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research to Regennova, Inc., a small disadvantaged business in Durham, North Carolina. The grant supports the development of an orally-available, effective, and well-tolerated drug to treat autosomal dominant polycystic kidney disease (ADPKD), which affects over 350,000 Americans. The project aims to create and...
This Project Grant award of $340,822 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to determine the molecular and cellular mechanisms by which heparan sulfate controls parathyroid hormone-related protein (PTHrP) signaling via the PTH type 1 receptor (PTHR). The research aims to characterize the binding properties of PTHrP and heparin/heparan sulfate...
This Project Grant award of $1,188,167 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under CFDA 93.847, the Diabetes, Digestive, and Kidney Diseases Extramural Research program, supports research to develop inhibitors of the sphingosine 1-phosphate (S1P) signaling pathway as potential therapies for chronic kidney disease (CKD). The primary awardee, Virginia Polytechnic Institute & State University (Virginia Tech), will work to improve the oral...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research, provides $587,212 to the University of Alabama at Birmingham (UAB) to conduct research on the role of the CDKN1A (P21) gene in polycystic kidney disease (PKD). The goal of the research is to determine how abnormal regulation of the P21 gene, which is involved in cell cycle control and tissue repair, contributes...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $199,999 to the University of Florida to develop innovative artificial intelligence (AI)-based methods to support the discovery of potent, orally available small-molecule heparanase inhibitors. The goal is to evaluate these novel heparanase inhibitors in murine models as a...
This federal Project Grant award of $151,643, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research on developing and evaluating Proteolysis Targeting Chimeras (PROTACs) to stabilize hypoxia-inducible factors (HIFs) as a potential therapeutic approach for inflammatory bowel disease (IBD). The principal investigator, Dr. Ornelas Sanchez, and his...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,439,769 project grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Southern California. This 5-year study, titled "PFAS Exposure and Diabetic Kidney Disease in Youth with Type 2 Diabetes: A Multi-Omic Approach for Prevention and Treatment," aims to investigate the link between exposure to per- and polyfluoroalkyl substances...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is funding research to investigate intracellular cholesterol biosynthesis as a regulator of polycystic kidney disease (PKD) progression. The $504,621 award to the University of Texas Southwestern Medical Center will support a 5-year research project to: 1) determine if reducing...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $640,001 to Yale University to conduct research on the mechanisms and function of the protein Polycystin-1 (PC1) in the context of autosomal dominant polycystic kidney disease (ADPKD). The key objectives are to: 1) determine if a specific 200 amino acid fragment of PC1 can...
This federal Project Grant award of $675,660.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award was granted to the Beth Israel Deaconess Medical Center, Inc. (Bidmc) to conduct research focused on understanding the regulation and requirements for coenzyme A (CoA) biosynthesis, and how dysregulation of CoA synthesis is related to metabolic diseases...